## W\% A \& Gex Godfrey Phillips India Ltd. (GPIL)



| Shareholding Pattern | $31^{\text {st }}$ Dec $\mathbf{1 3}$ |
| :--- | ---: |
| Foreign promoter | $25.1 \%$ |
| Indian Promoter | $46.0 \%$ |
| Institutional (Incl. FII) | $15.2 \%$ |
| Corporate Bodies | $0.8 \%$ |
| Public \& others | $13.0 \%$ |

Ruchita Maheshwari
Research Analyst
+91 2239268023
ruchita.maheshwari@nirmalbang.com
Sunil Jain - HOR, Retail
+91 2239268196

Good result...attractive valuation; BUY
Godfrey Phillips (GPIL) register a Total revenue growth of $18.3 \%$ YoY to Rs. 640.3 cr and up by $6.1 \%$ QoQ. EBITDA margin improved by 490bps YoY to 21.3\% in Q3FY14 owing to decline in input cost and jump in net revenue. PAT grew by 43.8\% YoY to Rs. 70.7cr during Q3FY14.

2 Strong revenue growth in Cigarette and Tea \& Other retail segment led total revenue up by 18.3\% YoY: Despite higher incidence of tax (up 18\% in last two years except for cigarettes $>65 \mathrm{~mm}$ in length), GPIL has registered a strong growth in Cigarette business by $16.9 \%$ YoY to Rs 562.9 cr driven largely by price hike. We believe that customers get accustomed to steep price rise as cigarettes are addictive by nature plus new addition of cigarette consumers every year will keep the demand of cigarettes undeterred. Plus, tea \& other retail reported a $29 \%$ YoY growth to Rs 77.5 cr .
\& Cigarette EBIT margin expanded by 500bps YoY: GPIL reported a magnanimous jump in Cigaretet EBIT margin by 500bps YoY and by 470bps QoQ to $20.6 \%$ in Q3FY14, suggesting recovery in cigarette volumes and price hike. However, we believe after $18 \%$ increase in tax incidence in the last 2 years (highest ever), there is greater probability of moderation in tax increase, going ahead (vote on account and not a regular budget due to general elections) would be conducive for volume recovery in our view.
Increasing activation in cigarettes through launch of 64 mm cigarette cushioning volumes without diluting margins: Increased traction in 64 mm segment is preventing a sharper volume contraction, in our view. More importantly, it is not diluting Cigarette margins. We believe market share gains, recruitment of new consumers are driving growth of 64 mm .
e. PAT grew by $44 \%$ YoY: PAT grew by $43.8 \%$ Yoy to Rs 70.7 cr and by $84.9 \%$ QoQ. Pat margin stood at $11.3 \%$ in Q3FY14, up by 200bps YoY and by 480bps QoQ. Despite higher tax outgo of $34.7 \%$ in Q3FY14 as against $28.6 \%$ in Q3FY13 and 32.5\% in Q2FY14, declin in Other income, the company reported substantial improvement in the pofitability of the company.

## Valuation \& Recommendation

On a trailing basis, GPIL is trading at a discount compared to ITC and VST by $+50 \%$ and $+17 \%$ respectively. We feel that the discount is unwarranted given the sharp improvement in the Cigarette EBIT margins in the last two quarters. In addition, the increase traction in 64 mm cigarette will keep the uptick in the volumes going forward without diluting its margins, in our view. Though, the Tea \& other retail segment have not broken-even (contributes $\sim \mathbf{1 2 \%}$ to the total revenue, will not negatively impact the operating margins in a big way. At CMP of Rs. 2760, GPIL is trading at a PE of 14.9x on a trailing basis. With sharp improvement in the Cigarette EBIT margins, expect cigarette volume recovery based on the belief that the year is unlikely to see any significant hike in excise duty, attractive valuations, we advise investors to BUY the stock for a further return of 15-20\% from hereon.

| Year <br> (cons) | Net Sales <br> (Rs cr) | Growth <br> $(\%)$ | EBIDTA | Margin <br> $(\%)$ | APAT (Rs <br> cr) | Margin <br> $(\%)$ | EPS (Rs.) | P/E (x) | P/BV <br> $(\mathbf{x})$ | RoE |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| FY10 | 1383.9 | $22.2 \%$ | 152.7 | $11.0 \%$ | 115.1 | $8.3 \%$ | 110.6 | 24.9 | 4.2 | $18.7 \%$ |
| FY11 | 1628.4 | $17.7 \%$ | 275.7 | $16.9 \%$ | 166.1 | $10.2 \%$ | 159.7 | 17.3 | 3.6 | $22.3 \%$ |
| FY12 | 1910.5 | $17.3 \%$ | 326.2 | $17.1 \%$ | 181.5 | $9.5 \%$ | 174.5 | 15.8 | 3.1 | $20.8 \%$ |
| FY13 | 2097.6 | $9.8 \%$ | 327.0 | $15.6 \%$ | 170.0 | $8.1 \%$ | 163.5 | 16.9 | 2.7 | $17.0 \%$ |

## Peer Comparison on trailing basis (last four quarters)

| Company name | Net <br> Sales | EBITDA | EBITDA\% | PAT | PAT\% | EPS | PE |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| GPIL | 2403.1 | 400.4 | $16.7 \%$ | 192.1 | $8.0 \%$ | 184.7 | 14.9 |
| ITC | 31917.7 | 11957.8 | $37.5 \%$ | 8435.2 | $26.4 \%$ | 10.7 | 29.9 |
| VST | 755.7 | 198.4 | $26.3 \%$ | 133.0 | $17.6 \%$ | 88.7 | 18.0 |

Source: Company and Nirmal Bang Research

## Company Description

Godfrey Phillips India (GPIL) is one of the largest players in the Indian cigarette industry and has two major stakeholders, the K. K. Modi Group and Philip Morris. The Company operates in two segments: Cigarette and tobacco products, and Tea and other retail products. The company's operations primarily span the entire northern and western part of the country with new markets like West Bengal and South of India. The company manufactures some of the most popular cigarette brands in the country like Four Square, Red \& White, Cavanders, Tipper and North Pole. The company has created popular products like Stellar, India's first slim cigarette and 'i-gen' a king-size cigarette, the first in India to conform to EU norms of 10-1-10 in their kitty. Godfrey Phillips India's global mindset also drew the company towards an arrangement with Philip Morris for manufacturing and sale of the iconic brand Marlboro in India. The Company cigarettes are manufactured in state-of-the-art factories at Guldhar, Andheri \& Rabale. The company enjoys 520 exclusive distributors and over 800,000 retail outlets.

GPIL also has a flourishing International Business Division through which it collaborates with some of the top players in the international tobacco industry to assist them in marketing their products and providing various professional and expert services including contract manufacturing, cut tobacco, smoke analysis and various other consultancy services. Many countries from the Middle East to West Africa, South East Africa, South East Asia, East Europe, Australia, South America, Southeast Asia and Central America have been added on to its portfolio of exporting cigarettes as well as cut tobacco.

## Q3FY14 Standalone Result Analysis

| Particulars | Q3FY14 | Q3FY13 | YoY\% | Q2FY14 | QoQ\% | 9MFY14 | 9MFY13 | YoY\% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Gross Sales | 1075.2 | 908.4 | 18.4\% | 1006.8 | 6.8\% | 3085.8 | 2598.2 | 18.8\% |
| Less: Excise Duty | 451.9 | 377.1 | 19.8\% | 416.3 | 8.6\% | 1271.8 | 1134.9 | 12.1\% |
| Net Sales | 623.4 | 531.3 | 17.3\% | 590.6 | 5.6\% | 1814.0 | 1463.3 | 24.0\% |
| Other Operating Income | 17.0 | 10.2 | 67.1\% | 12.9 | 31.3\% | 44.8 | 27.4 | 63.7\% |
| Total Income | 640.3 | 541.5 | 18.3\% | 603.5 | 6.1\% | 1858.8 | 1490.7 | 24.7\% |
| Increase / Decrease in Stock | -6.8 | -7.4 | -8.4\% | 2.6 | -356.8\% | 21.0 | -36.9 | -156.7\% |
| Consumption of raw material | 147.3 | 122.9 | 19.9\% | 131.2 | 12.3\% | 392.4 | 347.0 | 13.1\% |
| Purchase of traded goods | 103.4 | 94.0 | 10.0\% | 109.7 |  | 342.2 | 257.1 |  |
| Employees Cost | 55.4 | 49.2 | 12.7\% | 54.9 | 1.0\% | 169.5 | 146.0 | 16.1\% |
| Advertisement | 75.9 | 76.0 | -0.1\% | 71.7 | 5.8\% | 220.0 | 224.0 | -1.8\% |
| Other Expenditure | 132.1 | 119.7 | 10.4\% | 146.6 | -9.9\% | 416.0 | 335.0 | 24.2\% |
| Total Expenditure | 507.3 | 454.3 | 11.7\% | 516.8 | -1.8\% | 1561.0 | 1272.1 | 22.7\% |
| EBITDA | 133.0 | 87.2 | 52.6\% | 86.7 | 53.4\% | 297.8 | 218.6 | 36.2\% |
| Interest | 4.5 | 6.5 | -30.9\% | 13.9 | -67.6\% | 24.2 | 20.9 | 15.7\% |
| Other Income | 2.5 | 11.2 |  | 4.8 |  | 20.3 | 20.9 |  |
| PBDT | 131.0 | 91.9 | 42.7\% | 77.6 | 68.9\% | 293.9 | 218.7 | 34.4\% |
| Depreciation | 22.7 | 22.9 | -1.1\% | 21.0 | 8.2\% | 65.3 | 63.6 | 2.6\% |
| Exceptional item | 0.0 | 0.0 |  | 0.0 |  | 35.4 | 0.0 |  |
| PBT | 108.4 | 68.9 |  | 56.6 |  | 193.2 | 155.0 |  |
| Tax | 37.6 | 19.7 | 90.9\% | 18.4 | 104.6\% | 60.9 | 45.3 | 34.4\% |
| Reported Profit After Tax (PAT) | 70.7 | 49.2 | 43.8\% | 38.3 | 84.9\% | 132.3 | 109.7 | 20.6\% |
| EPS (Unit Curr.) | 68.0 | 47.3 |  | 36.8 |  | 127.3 | 105.5 |  |
| Equity | 10.4 | 10.4 |  | 10.4 |  | 10.4 | 10.4 |  |
| Face Value | 10 | 10 |  | 10 |  | 10 | 10 |  |
|  |  |  | BPS |  | BPS |  |  | BPS |
| EBITDA(\%) | 21.3\% | 16.4\% | 490 | 14.7\% | 660 | 16.4\% | 14.9\% | 150 |
| PBDT(\%) | 21.0\% | 17.3\% | 370 | 13.1\% | 790 | 16.2\% | 14.9\% | 130 |
| PAT(\%) | 11.3\% | 9.3\% | 200 | 6.5\% | 480 | 7.3\% | 7.5\% | -20 |

Source: Company and Nirmal Bang Research

Q3FY14 Standalone Segment Analysis

|  | Q3FY14 | Q3FY13 | YoY\% | Q2FY14 | QoQ\% | 9MFY14 | RMFY13 | YoY\% |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Particulars | 562.9 | 481.4 | $16.9 \%$ | 526.7 | $6.9 \%$ | 1651.5 | 1344.2 | $22.9 \%$ |
| Cigarette | 77.5 | 60.1 | $29.0 \%$ | 76.8 | $0.9 \%$ | 207.3 | 146.5 | $41.5 \%$ |
| Tea \& other retail | 640.3 | 541.5 | $18.3 \%$ | 603.5 | $6.1 \%$ | 1858.8 | 1490.7 | $24.7 \%$ |
| Gross Sales |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| Segment Revenues (Profit / Loss) | 115.81 | 75.21 | $54.0 \%$ | 83.66 | $38.4 \%$ | 246.76 | 176.5 | $39.8 \%$ |
| Cigarette | $20.6 \%$ | $15.6 \%$ |  | $15.9 \%$ |  | $14.9 \%$ | $13.1 \%$ |  |
| margin | -8.93 | -3.79 |  | -7.21 |  | -25.05 | -9.55 | $162.3 \%$ |
| Tea \& other retail | $-11.5 \%$ | $-6.3 \%$ |  | $-9.4 \%$ |  | $-12.1 \%$ | $-6.5 \%$ |  |
| margin | 106.88 | 71.42 | $49.6 \%$ | 76.45 | $39.8 \%$ | 221.71 | 166.95 | $32.8 \%$ |
| Total |  |  |  |  |  |  | 24.18 | 20.89 |

Source: Company and Nirmal Bang Research
Consolidated Balance Sheet
Rs. in crore

| Particulars | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| SOURCES OF FUNDS: |  |  |  |  |  |
| Total Share Capital | 10.4 | 10.4 | 10.4 | 10.4 | 10.4 |
| Reserves Total | 586.3 | 671.0 | 794.9 | 925.7 | 1,047.0 |
| Net Worth | 596.7 | 681.4 | 805.3 | 936.1 | 1,057.4 |
| Minority Interest | 2.9 | 2.6 | 2.3 | 2.0 | 1.9 |
| Total Loans | 95.3 | 114.6 | 225.5 | 329.5 | 303.6 |
| Net Deferred Tax | -1.3 | 2.2 | 0.3 | -6.0 | 5.1 |
| Total Liabilities | 693.6 | 800.8 | 1,033.4 | 1,261.6 | 1,367.9 |
| APPLICATION OF FUNDS : |  |  |  |  |  |
| Net Block | 233.3 | 286.9 | 323.7 | 566.8 | 741.4 |
| Capital Work in Progress | 62.7 | 73.5 | 182.0 | 139.0 | 16.3 |
| Total Fixed Assets | 296.0 | 360.4 | 505.7 | 705.8 | 757.7 |
| Investments | 215.5 | 194.8 | 322.0 | 325.3 | 286.0 |
| Current Assets, Loans \& Advances |  |  |  |  |  |
| Inventories | 368.6 | 365.4 | 354.0 | 381.7 | 543.4 |
| Sundry Debtors | 30.4 | 49.3 | 45.4 | 75.0 | 79.3 |
| Cash and Bank | 18.9 | 36.3 | 54.0 | 24.2 | 24.5 |
| Loans and Advances | 77.7 | 80.6 | 56.7 | 95.6 | 77.7 |
| Others | 0.0 | 0.0 | 47.1 | 48.6 | 48.1 |
| Total Current Assets | 495.6 | 531.5 | 557.2 | 625.0 | 772.9 |
| Total Current Liabilities \& Provisions | 313.6 | 286.0 | 351.5 | 394.4 | 448.7 |
| Net Current Assets | 182.0 | 245.6 | 205.7 | 230.6 | 324.2 |
| Miscellaneous Expenses not written off | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Assets | 693.6 | 800.8 | 1,033.4 | 1,261.6 | 1,367.9 |

Source: Company and Nirmal Bang Research

Consolidated Income Statement Analysis

Rs. in crore

| Particulars | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Net Sales | 1,132.1 | 1,383.9 | 1,628.4 | 1,910.5 | 2,097.6 |
| Total Expenditure | 981.6 | 1,231.2 | 1,352.7 | 1,584.3 | 1,770.7 |
| EBITDA | 150.5 | 152.7 | 275.7 | 326.2 | 327.0 |
| EBITDA Margin | 13.3\% | 11.0\% | 16.9\% | 17.1\% | 15.6\% |
| Depreciation \& Amortization | 31.1 | 37.6 | 43.9 | 66.9 | 92.6 |
| Other Income | 52.2 | 61.7 | 23.2 | 29.7 | 29.4 |
| PBIT | 171.7 | 176.8 | 255.0 | 289.0 | 263.8 |
| Interest | 5.9 | 6.9 | 13.6 | 31.7 | 26.9 |
| PBT | 165.9 | 169.9 | 241.4 | 257.3 | 236.9 |
| Total Tax | 57.6 | 50.2 | 75.5 | 76.3 | 67.4 |
| PAT | 108.2 | 119.7 | 165.9 | 181.1 | 169.4 |
| PAT Margin | 9.6\% | 8.7\% | 10.2\% | 9.5\% | 8.1\% |
| Minority items | -0.3 | -0.3 | -0.3 | -0.3 | -0.2 |
| Profit/loss of associate cos | 0.0 | -5.0 | 0.0 | 0.2 | 0.4 |
| Adj PAT | 108.6 | 115.1 | 166.1 | 181.5 | 170.0 |
| Adj PAT Margin | 9.6\% | 8.3\% | 10.2\% | 9.5\% | 8.1\% |
| Equity Capital | 10.4 | 10.4 | 10.4 | 10.4 | 10.4 |
| EPS | 104.4 | 110.6 | 159.7 | 174.5 | 163.5 |

Source: Company and Nirmal Bang Research

Key metrics

|  |  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Operational Ratio | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 |
| EBITDA margin (\%) | $13.3 \%$ | $11.0 \%$ | $16.9 \%$ | $17.1 \%$ | $15.6 \%$ |
| APAT margin (\%) | $9.6 \%$ | $8.3 \%$ | $10.2 \%$ | $9.5 \%$ | $8.1 \%$ |
| APAT Growth (\%) | $21.6 \%$ | $6.0 \%$ | $44.4 \%$ | $9.3 \%$ | $-6.3 \%$ |
| Price Earnings (x) | 26.4 | 24.9 | 17.3 | 15.8 | 16.9 |
| Book Value (Rs.) | 573.7 | 655.2 | 774.3 | 900.1 | 1016.8 |
| ROCE (\%) | $18.1 \%$ | $17.6 \%$ | $20.6 \%$ | $19.3 \%$ | $16.0 \%$ |
| RONW (\%) | $34.2 \%$ | $18.7 \%$ | $22.3 \%$ | $20.8 \%$ | $17.0 \%$ |
| Debt Equity Ratio | 0.2 | 0.2 | 0.3 | 0.4 | 0.3 |
| Price / Book Value (x) | 4.8 | 4.2 | 3.6 | 3.1 | 2.7 |
| EV / Sales | 1.3 | 1.1 | 1.0 | 0.9 | 0.9 |
| EV / EBIDTA | 19.6 | 19.3 | 11.0 | 9.7 | 9.6 |

Source: Company and Nirmal Bang Research

## Disclaimer:

This Document has been prepared by Nirmal Bang Research (A Division of Nirmal Bang Securities PVT LTD). The information, analysis and estimates contained herein are based on Nirmal Bang Research assessment and have been obtained from sources believed to be reliable. This document is meant for the use of the intended recipient only. This document, at best, represents Nirmal Bang Research opinion and is meant for general information only. Nirmal Bang Research, its directors, officers or employees shall not in anyway be responsible for the contents stated herein. Nirmal Bang Research expressly disclaims any and all liabilities that may arise from information, errors or omissions in this connection. This document is not to be considered as an offer to sell or a solicitation to buy any securities. Nirmal Bang Research, its affiliates and their employees may from time to time hold positions in securities referred to herein. Nirmal Bang Research or its affiliates may from time to time solicit from or perform investment banking or other services for any company mentioned in this document.

# Nirmal Bang Research (Division of Nirmal Bang Securities PVT LTD) 

> B-2, 301/302, Marathon Innova,
> Nr. Peninsula Corporate Park
> Lower Parel(W), Mumbai-400013
> Board No. : 91223926 8000/8001

Fax. : 02239268010

